ArticleMikrochimica acta2026
Magnetic boronate-Ti(IV) dual-affinity nanoparticles for simultaneous enrichment and sequential elution of glycopeptides and phosphopeptides.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The simultaneous enrichment of glycopeptides and phosphopeptides from complex peptide mixtures remains challenging because boronate affinity and immobilized metal ion affinity chromatography (IMAC) typically require different pH conditions for efficient binding. We evaluated the previously reported dual boronate-Ti(IV) magnetic nanomaterial, Mag@DBA-Ti(IV), as a sample-preparation platform for the single-sorbent, single-loading-condition enrichment and sequential elution of glycopeptides and phosphopeptides. The material, prepared by co-immobilizing a low-pKₐ boronic acid ligand and alendronate on magnetic nanoparticles, followed by Ti(IV) chelation, was originally developed for small-molecule enrichment; its translation to peptide-level proteomics is established here. The integrated boronate and Ti(IV)-IMAC sites enabled concurrent binding of glycopeptides and phosphopeptides under neutral loading conditions, with selective release achieved using acidic and alkaline eluents, respectively. This translation required redesigning the elution chemistry for MS compatibility, replacing the high-pH sodium phosphate eluent used for small molecules with 0.4 mol L⁻¹ NH₃·H₂O, and establishing that the dual-affinity sites retain selectivity when glycopeptides and phosphopeptides are low-abundance species competing with a large excess of unmodified peptides. Mag@DBA-Ti(IV) exhibited high adsorption capacities toward model protein digests, reaching 71.4 mg g⁻¹ for IgG digest and 125 mg g⁻¹ for α-casein digest. The material also showed high selectivity for both glycopeptides and phosphopeptides in the presence of a 500-fold excess of bovine serum albumin digest, allowing detection at concentrations as low as 10⁻¹⁰ mol L⁻¹. When applied to U251 cell lysate digests, Mag@DBA-Ti(IV) enabled the identification of 1,945 glycopeptides from 752 glycoproteins and 7,498 phosphopeptides from 2,410 phosphoproteins in a single experiment. These results demonstrate that the dual boronate-Ti(IV) affinity concept, originally established for small molecules, can be translated to peptide-level bottom-up proteomics, providing a single-sorbent route to integrated glycoproteomic and phosphoproteomic determination.
Indexed as
Identifiers
42886272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.